Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized Idiotype Cancer Vaccine
- Development stage
- Preclinical
- Lead developer
- Renhaim
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Personalized Idiotype Cancer Vaccine is an investigational mRNA-based immunotherapy being developed by Renhaim for the treatment of B-cell lymphoma and other antibody-producing malignancies. The vaccine is engineered using the variable region sequences of the antigen-binding fragment (Fab) of antibodies (the idiotype) unique to an individual patient's tumor cells. By delivering mRNA that encodes these patient-specific sequences, the vaccine is designed to trigger the immune system to recognize and eliminate malignant B-cells expressing the specific idiotype. This personalized approach aims to provide a highly targeted therapy with minimal off-target effects on healthy cells.
- Other names
- Renhaim personalized idiotype mRNA vaccinemRNA idiotype cancer vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)
Beyond the preview
Go deeper on Personalized Idiotype Cancer Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized Idiotype Cancer Vaccine.